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Digital ulcers are a very frequent complication of systemic sclerosis affecting about half of the SSc patients, and about 75% of
the affected patients have their first DU episode within 5 years from their first non-Raynaud symptom. The lack of adequate
classification criteria as well as the lack of knowledge of the development of DU have contributed to the opening of specific
registries to better understand the natural history of these lesions. For these reason, specific disease registries play a fundamental
role in this field of research. Thanks to the systematic collection of data and their subsequent analysis and comparison between
different cohorts, it is possible to improve understanding of the underlying trigger mechanisms of DU development and to
determine temporal trends. In the future, the development of recommendations for the management of DU remains of pivotal
importance to prevent DU development and obtain rapid healing as well as reduction of pain and disability.
1. Introduction
Digital ulcers (DUs) are a very frequent complication of
systemic sclerosis (SSc) that affects almost half of the
patients, either with limited (lSSc) or diffuse (dSSc) subset
of the disease. About 75% of the affected patients have their
first DU episode within 5 years from their first non-Raynaud
symptom [1–3].
The aetiology of DU is complex and multifactorial.
The principal mechanisms underlying the DU formation
are ischemic, mechanic, and inflammatory, alone or in
combination, acting over the SSc vasculopathy [4]. In fact,
there are at least three types of DU: those localized in the
acral parts of the body, as the fingertips, mainly resulting
from an ischemic process, those localized on the dorsal aspect
of the fingers where the skin retraction due to fibrosis over
bony prominences seems to be the main cause and those
evolved on a pitting scar or subcutaneous calcinosis due to
a localized inflammatory irritative mechanism [1, 5].
In recent years, the increasing interest for the effects
of drugs on healing and prevention of new ulcers and
the awareness of the importance of DU for the Quality
of life (QoL) of SSc patients, have led to the opening of
specific registries to better understand the natural history
and evolution of DU.
The present report provides an overview of the DU
specific registries that are at the moment available and of the
disease registries containing data on DU.
2. The Burden of DU
In SSc, DUs are a persistent and often recurrent compli-
cation, difficult to manage and slow to heal and can cause
tissue loss [6]. Furthermore, DUs are frequently infected and
may lead to osteomyelitis, gangrene, autoamputation, and in
some cases to septicaemia [7].
DUs are also very painful with a disabling effect on
patients, limiting hand function and daily activities, such as
feeding, dressing, and hygiene [8]. The net effect is the heavy
QoL impairment [9]. Indeed, the progressive scarring and
tissue loss, that patients experience daily, can lead to severe
social and self-esteem problems [10]. Moreover, severe cases
of DU required frequent hospitalization with an elevated
burden for the health care system and for the families due
to the leave from work [8].
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3. The Scleroderma Digital Ulcers Database
(DAS-DU)
The DAS-DU was created in 2004, in the Scleroderma
Ulcer Care Unit of the Division of Rheumatology of the
University of Florence, to collect information on SSc DU
and their management [5]. The DAS-DU includes basic
clinical and demographic data that could be useful in clinical
trials. Initially, the database was based on a system of
paper datasheets that were then stored in chronological
order. Despite being a valuable support to understanding
the natural history of DU, in practice, this initiative has
also identified a number of problems related to opening a
long-term database. First, a larger amount of clinical data
on DU required a continuous update of the database that
was still insufficient to achieve the objective of this initiative.
Secondly, the difficulty in data collection and statistical
analysis with the paper-based system has led us to create a
new electronic database to meet the needs of the progress
of knowledge. The database is now maintained on an Access
platform stored on a protected offline dedicated computer
with anonymised data. All patients are associated with a
unique ID, while all DU episodes in a single patient have a
secondary unique ID.
Actually, the DAS-DU represents one of the largest and
best characterized DU specific database of a single center
SSc cohort. Good quality clinical information on more than
100 SSc patients with more than 2000DU episodes has been
recorded on the database. The dataset collected includes
main DU characteristics such as localization (fingertips, nails
area, dorsal, and palmar aspect of the finger), dimensions
(area in mm2), bed of the lesion (reepithelialisation, granula-
tion tissue, fibrin, wet or dry necrosis, eschar, and gangrene),
exudate (low, high or pus), borders of the lesions (regular
or irregular), perilesional skin (normal or inflamed) and
oedema, bone and tendons exposure, and autoamputation.
Every DUwas also staged in superficial (partial thickness skin
loss involving epidermis), intermediate (full thickness skin
loss involving damage to or necrosis of subcutaneous tissue
that may extend down to, but not through underlying fascia),
or deep (full thickness skin loss with extensive destruction
or damage to muscle down over the fascia, supporting
structures and bone). A pain scale (NRS 0–10) and the
Cochin Hand function also known as the Duruo¨z hand
functional disability scale [11, 12] were also included in the
main dataset.
Essentially this database reflects the clinical practice in
the Scleroderma Ulcer Care Unit of our centre which has
generated a significant amount of specific consistent data
on the main characteristics of DU integrated with clinical
features. This has ensured quality and accuracy of the data
collected.
The majority of SSc patients included in the DAS-DU
(2004–2008) were limited SSc (70%), most were Caucasian
women (86%),mean age of patients was 58 (57.7±15.1 years)
with a cumulative mean number of DU of 15.7 ± 17, 7 over
the four years followup [5]. The majority were observed in
lSSc (72%) although the frequency of recurrent DU (61%)
were higher in dSSc. DU were most frequently localized on
fingertips (55%) with a mean dimension of 50mm2. Mean
features of DU were irregular borders of the lesion (80%),
and the presence of oedema and inflammation of perilesional
skin (75%), and an intermediate stage (60%). Spontaneous
moderate to severe pain was always present and is very
frequently associated with infection. Despite the treatment,
gangrene may occur and osteotendinous exposure (43%)
and infection (40%) were frequently observed and required
surgical amputation (14%). The database allowed also the
record of the time to healing which was about 80 days [5] and
also showed that DU, developed on a pre-existing calcinosis,
had an increased time to healing to about 95 days and to over
280 days for those derived from gangrene.
4. The Digital Ulcers Outcome (DUO) Registry
The DUO Registry, meeting a postapproval commitment
to the European Medicines Agency (EMEA), was started in
April 2008 to collect information on DU associated with
SSc and their management. In this registry, SSc patients
with ongoing DU are enrolled to track key information
of the clinical course and outcome of DU and to collect
safety information on the use of bosentan, a dual endothelin
receptor antagonist approved in Europe for reducing the
number of new DU in SSc.
The registry is an European, multicenter, prospective,
observational, noninterventional program for patients with
DU/SSc. Participating patients undergo assessments and
receive medical or surgical therapies according to their physi-
cian’s judgment. Patients do not receive any experimental
intervention or treatment as a result of their participation in
the registry. Data are collected via a secure server based on
the Internet where the access was guaranteed for registered
users only. In order to protect privacy, a unique identifier was
assigned to each patient.
The dataset includes demographics, past history and
present status of the disease and DU, complications like
soft tissue infection, gangrene or osteomyelitis, and care
protocols including topical medications, drugs, and surgical
interventions. From April 2008 to May 2009, 648 patients
have been enrolled, with 47% lSSc, 41% dSSc, and 9%
of overlap/mixed CTD. The mean age was higher for lSSc
patient (56.2 years SD:13.4) than dSSc patients (50.8 years
SD:14). Preliminary data analysis, still unpublished, shows
that more than half of patients needed hospitalization for
complications or intervention (59% of lSSc and 52% of
dSSc). The most frequent complication observed was soft
tissue infection requiring antibiotics (44.5% of lSSc and
40.5% of dSSc), followed by gangrene (34% of lSSc and
26.5% of dSSc) and finally by surgical amputation (17% of
lSSc and 11% of dSSc) [13].
5. The German Network for Systemic
Scleroderma (DNSS) Registry
The DNSS registry was founded in 2003 and includes demo-
graphic information of SSc patients and signs and symptoms
of organ involvement (heart, lung, gastrointestinal tract,
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kidney, musculoskeletal system, nervous system, and skin),
characteristic laboratory data such as antinuclear antibodies,
ESR and CK serum levels, as well as information on physical
and on systemic therapies.
In 2008, a statistical study on more than 1880 SSc
patients was performed to detect possible risk factors for the
development of DU [14]. About 24% of the patients had
active ulcers at the time of entering on the DNSS register.
As expected, Raynaud phenomenon (RP) was the most
prevalent symptom with a slightly higher prevalence in DU
patients (98% versus 94%). Lung fibrosis was significantly
higher in patients with DU (45% versus 33%) as well as
pulmonary arterial hypertension (PAH: 24% versus 13%),
heart (18% versus 13%), upper gastrointestinal (18% versus
13%), and oesophageal involvement (71% versus 57%).
Also skin sclerosis (95%) and mouth involvement (36%)
were associated with DU. The multivariate analysis of data
obtained by comparing patients with or without DU showed
that male sex, pulmonary arterial hypertension, oesophageal
involvement, the extent of skin sclerosis assessed by the
modified Rodnan Skin Score (mRSS), presence of anti-Scl-
70 antibodies, young onset of Raynaud’s phenomenon (RP),
and an elevated ESR represent significant risk factors for the
occurrence of DU in SSc. In addition, univariate analysis
showed that the above factors and the presence of diffuse
subset of disease (dSSc), pulmonary fibrosis and involvement
of the upper gastrointestinal tract, and heart involvement are
more common in patients with DU representing an elevated
relative risk for DU.
Moreover, the combination of male gender, early onset of
RP, an ESR >30mm at the first hour, anti Scl-70 positivity
and gastrointestinal and pulmonary arterial involvement
showed the highest probability of developing DU (88%)
[14].
After all, the DNSS registry showed a heterogeneity
between centres for the DU management. In fact, only the
21% of patients with DU received prostacyclins and 40% of
patients with DU did not receive a vasoactive therapy, and
even in 27.8% of patients who already suffered from DU at
the time of initial registration in the DNSS centres, calcium
channel blockers was the only therapy. Bosentan (5.5%)
and sildenafil (3.4%) are infrequently prescribed in these
patients. It was remarkable that 56% of patients with DU
performed physiotherapy with paraffin kneading or baths
and lymph drainage [15].
6. Canadian Scleroderma Research Group
(CSRG) Registry
The CSRG have collected annually data on presence, loca-
tion, and number of DU with their complications and other
organ involvement and skin score on their SSc cohort to
determine possible associations of DU with other factors
such as internal organ complications.
Out of the 938 patients enrolled, 86% were women with
a mean age of 56 years, a disease duration of about 13 years
and 53% with lSSc. Fifteen percent patient had currently a
DU, 45% had a DU ever, and 53% had pitting scars. Digital
necrosis were found on 1.8% of patients and amputation in
about 7%.
A significant association were found with increased
disease duration, younger age at the disease onset, Scl-
70 autoantibodies, interstitial lung disease, reduced DLCO,
increased mRSS, and hands and fingers skin score but no
associations with smoking habits, gender, or other structural
vasculopathy marker as PAH. It is to be noted that patients
with diffuse SSc subset are nearly twice more likely to
experience DU than patients with lSSc. Finally, DUs were
associated with an increased burden of disease, as assessed
by HAQ [16].
7. EULAR Scleroderma Trial and Research
(EUSTAR) Group
EUSTAR has been founded in 2003 and theminimal essential
data set (MEDS) has been created to allow all the members
to store their data. In the first analysis of the database, which
included a total of 3656 patients (1349 with dSSc and 2101
with lSSc) enrolled in over than 100 centres worldwide,
DU resulted to be in 42.7% of patients with dSSc and
about 33% of lSSc patients. In both subsets, patient with
earlier onset of Raynaud’s phenomenon had DU more often
than those with a late onset (51% versus 35% in dSSc and
39% versus 28% in lSSc) [2]. Moreover, a difference of
prevalence of DU in association with autoantibodies was
demonstrated. Indeed, the prevalence was 36.7% with ANA
positive, 44.8% with Scl70 positive, and 31.2% with ACA
positive [2]. This has led EUSTAR to start a DU observational
study with a retrospective and a prospective phase, opened
to all member centres, with the aim to describe the natural
history, treatment patterns, and outcomes of DU disease in a
multinational cohort of incident DU patients. Actually, more
than 120 patients have already been enrolled in retrospective
phase and about 60 in perspective. Preliminary data will be
available soon. Single center and national registries, as above
mentioned, are very useful to understand the prevalence and
incidence of DU in SSc but an international registry remains
of invaluable utility to understand the overall behaviour of
DU in SSc and its clinical features as well as being a solid
base for large scale clinical and basic studies.
8. Assessment and Outcome Measure
The definition of outcome measure and indicators of DU
severity is perhaps the main purpose of the DU registries. In
recent years, several trials have studied the effects of drugs on
healing or prevention of DU [10, 17–20] but, analyzing these
studies, it is clear that DUs are differently defined and there is
disagreement on the outcome measures used.
At the best of our knowledge, there are a considerable
number of possible markers of DU severity: dimensions,
depth, localization, origin, loss of tissue with bone and
tendon exposure, inflammation or infection of perilesional
tissues, pain, and loss of hand function [5]. A large and deep
DU is associated with longer time to healing as well as the
bone exposure might be associated with osteomyelitis that
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may require surgical amputation [5]. Loss of hand function,
hand disability, and QoL may also become markers of DU
severity because they may have a substantial impact on
patient well-being [9].
Localization may be helpful in determining the main
trigger of DU. Usually, DU over the finger joints have been
considered mechanical, mainly due to skin retraction and
independent from ischemia [1] as the dorsal microvascular
perfusion seemsmaintained in these area while themicrovas-
cular alterations are concentrated on the fingertips [21].
Pain is a pivotal symptom because it seems associated
with severity of DU. Spontaneous moderate to severe pain
is almost always present in large and deep DU, probably due
to the extensive ischemia in the underlying tissues, but the
presence of severe pain at DU presentation or the worsening
of painmay be linked, in themajority of cases, with infection.
Thus, the cause of pain must be carefully investigated in daily
practice [5].
The past history of DU or DU as early manifestation of
SSc may be a predictor of the future course and may help
physicians in selecting a preventive aggressive treatment.
9. Conclusion
In SSc, a clinical classification of DU is still lacking, and today
the treatment and prevention of DU represent a stimulating
challenge for all rheumatologists.
The increasing number of clinical trials on DU highlights
the need to increase knowledge of the mechanisms under-
lying the formation of DU in SSc. This has been the main
reason for the creation of specific DU registries that have now
a fundamental role in this field of research.
Thanks to the systematic collection of data and their sub-
sequent analysis and comparison between different cohorts,
it is possible to improve understanding of the different
aspects of DU development and to determine therapeutic
temporal trends [22–24].
The weak points of these registries, however, remain
the lack of unambiguous criteria for the assessment of DU
that are potential for selection bias, as well as the lack of
data verification and probably patients are not monitored
as rigorously as in randomized controlled studies (RCTs)
thus leading to underestimation of the rate of some “events”.
Moreover, the lack of internationally accepted outcome
measure has led to nonuniformity of the published. This
evidence suggests to the community the urgent need to
design a common strategy on DU mainly based on scientific
evidence. Moreover, the DU classification still remains an
unmet need that indeed may be helpful in identifying those
lesions to be included or excluded from clinical trials [25].
The discrepancy of results in efficacy of some drugs seen in
the trials published until today, may be probably due to the
multifactorial pathogenesis of DU. In fact, DU caused by a
predominantly ischemic process may be more responsive to
vasoactive therapy than those caused by skin retraction or
calcinosis.
There are some differences between disease registries and
registries created for a specific feature of the disease. Data
from a specific registry are more accurate than those derived
from a general disease registry. In fact, some “event” might
be underestimated, probably due to the amount of data
included to the aim of the registry which is often to verify
the natural course of disease and response to therapies. For
this reason, it is fundamental to create specific registries, like
EUSTAR and DUO registry, whose sole purpose is to study
ongoing DU in SSc.
In the future, the development of recommendations
for the management of DU remains of pivotal importance
to obtain rapid healing as well as reduction of pain and
disability.
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